Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Clinical colorectal cancer"
DOI: 10.1016/j.clcc.2019.04.003
Abstract: BACKGROUND Current guidelines of the National Comprehensive Cancer Network and the European Society of Medical Oncology recommend regorafenib or trifluridine/tipiracil (TAS-102) for third-line therapy of metastatic colorectal cancer (mCRC). We evaluated the impact of regorafenib… read more here.
Keywords: muscle; tas 102; cancer; skeletal muscle ... See more keywords
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical colorectal cancer"
DOI: 10.1016/j.clcc.2021.06.002
Abstract: INTRODUCTION There have been significant developments in colorectal cancer (CRC) research over the last few years, with the introduction of new agents that have been prolonged median overall survival of metastatic colorectal cancer (mCRC). These… read more here.
Keywords: treatment; colorectal cancer; cancer; mcrc patients ... See more keywords
Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Current problems in cancer"
DOI: 10.1016/j.currproblcancer.2021.100793
Abstract: For patients with refractory metastatic colorectal cancer (mCRC) treatment with Trifluridine/Tipiracil, also known as TAS-102, improves overall survival. This study aims to investigate the efficacy and safety of TAS-102 in a real-world population from Victoria,… read more here.
Keywords: metastatic colorectal; treatment; colorectal cancer; refractory metastatic ... See more keywords
Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.
Sign Up to like & getrecommendations! Published in 2017 at "European journal of cancer"
DOI: 10.1016/j.ejca.2017.08.033
Abstract: BACKGROUND Trifluridine (FTD) is an active cytotoxic component of the metastatic colorectal cancer (mCRC) drug TAS-102, and thymidine phosphorylase inhibitor (TPI) inhibits the rapid degradation of FTD. We tested whether single nucleotide polymorphisms (SNPs) in… read more here.
Keywords: metastatic colorectal; ent1 mate1; colorectal cancer; cohort ... See more keywords
APOLLON: A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.3523
Abstract: 3523Background: APOLLON is an open-label, single-arm phase I/II study investigating the efficacy and safety of panitumumab (Pmab) in combination with TAS-102 (trifluridine/tipiracil) in pts with RA... read more here.
Keywords: phase study; panitumumab; tas 102; apollon ... See more keywords
Efficacy, tolerability, and manageability of TAS-102 plus bevacizumab for metastatic colorectal cancer patients in clinical practice.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e15535
Abstract: e15535Background: The C-TASK FORCE trial demonstrated that TAS-102 plus bevacizumab might become a potential treatment option for patients with metastatic colorectal cancer (mCRC) in a refractory s... read more here.
Keywords: 102 plus; metastatic colorectal; colorectal cancer; tas 102 ... See more keywords
A phase I/II study of trifluridine/tipiracil (TAS-102) in combination with nanoliposomal irinotecan (NAL-IRI) in advanced GI cancers.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps4155
Abstract: TPS4155Background: Trifluridine/tipiracil (FTD/TPI, also known as TAS-102) is a combination of a nucleoside analogue and a thymidine phosphorylase inhibitor. TAS-102 has shown activity in 5FU-resis... read more here.
Keywords: 102 combination; tas 102; trifluridine tipiracil;
A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer (HGCSG1503): Analysis of cases of prior regorafenib.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.832
Abstract: 832Background: The J003 trial and RECOURSE trial revealed the safety and efficacy of TAS-102 for patients with metastatic colorectal cancer (mCRC). In March 2014, TAS-102 was approved in Japan. How... read more here.
Keywords: metastatic colorectal; safety efficacy; 102 patients; patients metastatic ... See more keywords
Factors associated with efficacy of TAS-102 in patients with refractory metastatic colorectal cancer (mCRC).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.858
Abstract: 858Background: TAS-102 significantly improved progression free survival (PFS) and overall survival (OS) versus placebo in patients with treatment refractory mCRC. We analyzed potential predictive and prognostic factors in patients treated with TAS-102 in real-world practice.… read more here.
Keywords: mcrc; 102 patients; efficacy tas; factors associated ... See more keywords
Regorafenib with TAS-102 (REGOTAS) in metastatic colorectal cancer patients who progressed after at least two standard therapies: Efficacy and safety results of a multicenter phase I study (REMETY).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.4_suppl.158
Abstract: 158Background: The multi-kinase inhibitor regorafenib (REGO) and oral fluoropyrimidine TAS-102 (TAS) show efficacies as single agents in treatment of refractory metastatic CRC patients (pts). We co... read more here.
Keywords: regotas metastatic; metastatic colorectal; 102 regotas; regorafenib tas ... See more keywords
The pretreatment lymphocyte-to-monocyte ratio (LMR) to predict treatment efficacy and prognosis in metastatic colorectal cancer treated with the combination of TAS-102 and bevacizumab (TAS-CC3 Study).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.4_suppl.224
Abstract: 224Background: The combination regimen of TAS-102 and bevacizumab as salvage-line therapy for metastatic colorectal cancer (mCRC) was established based on its high clinical effectiveness (C-TASK FO... read more here.
Keywords: combination; metastatic colorectal; colorectal cancer; 102 bevacizumab ... See more keywords